Literature DB >> 23968993

Multifaceted roles of ultra-rare and rare disease patients/parents in drug discovery.

Jill Wood1, Lori Sames, Allison Moore, Sean Ekins.   

Abstract

Individual parents and patients are increasingly doing more to fund, discover and develop treatments for rare and ultra-rare diseases that afflict their children, themselves or their friends. They are performing roles in business development that would be classed as entrepreneurial; and their organizational roles in driving the science in some cases are equivalent to those of principal investigators. These roles are in addition to their usual positioning as advocates. Through their efforts and those of the collaborative networks that they have developed, they could be positioned to disrupt the usual course of drug discovery. This can be illustrated using three different ultra-rare disease parent/patient advocate groups and the diseases for which they are developing treatments. This represents an alternative model for pharmaceutical research.
Copyright © 2013 Elsevier Ltd. All rights reserved.

Entities:  

Mesh:

Year:  2013        PMID: 23968993     DOI: 10.1016/j.drudis.2013.08.006

Source DB:  PubMed          Journal:  Drug Discov Today        ISSN: 1359-6446            Impact factor:   7.851


  19 in total

1.  Examining Physician Interactions with Disease Advocacy Organizations.

Authors:  Caroline Horrow; Joel E Pacyna; Carol Cosenza; Richard R Sharp
Journal:  AJOB Empir Bioeth       Date:  2019-08-26

2.  Enabling Anyone to Translate Clinically Relevant Ideas to Therapies.

Authors:  Sean Ekins; Natalie Diaz; Julia Chung; Paul Mathews; Aaron McMurtray
Journal:  Pharm Res       Date:  2016-09-12       Impact factor: 4.200

Review 3.  The role of brain tumor advocacy groups.

Authors:  Michele Rhee; Paulius Mui; Carl Cadogan; Jonny Imerman; Sarah Lindsell; Lainey Titus Samant
Journal:  Curr Neurol Neurosci Rep       Date:  2014-04       Impact factor: 5.081

4.  Industrializing rare disease therapy discovery and development.

Authors:  Sean Ekins
Journal:  Nat Biotechnol       Date:  2017-02-08       Impact factor: 54.908

Review 5.  Involving patients in reducing decision uncertainties around orphan and ultra-orphan drugs: a rare opportunity?

Authors:  Devidas Menon; Tania Stafinski; Andrea Dunn; Hilary Short
Journal:  Patient       Date:  2015-02       Impact factor: 3.883

Review 6.  [Orphan drugs : New opportunities for the treatment of rare diseases].

Authors:  M Beck
Journal:  Internist (Berl)       Date:  2016-11       Impact factor: 0.743

7.  Effect of Cysteamine on Mutant ASL Proteins with Cysteine for Arginine Substitutions.

Authors:  Corinne Inauen; Véronique Rüfenacht; Amit V Pandey; Liyan Hu; Henk Blom; Jean-Marc Nuoffer; Johannes Häberle
Journal:  Mol Diagn Ther       Date:  2016-04       Impact factor: 4.074

8.  Bigger data, collaborative tools and the future of predictive drug discovery.

Authors:  Sean Ekins; Alex M Clark; S Joshua Swamidass; Nadia Litterman; Antony J Williams
Journal:  J Comput Aided Mol Des       Date:  2014-06-19       Impact factor: 3.686

9.  Incentives for Starting Small Companies Focused on Rare and Neglected Diseases.

Authors:  Sean Ekins; Jill Wood
Journal:  Pharm Res       Date:  2015-12-14       Impact factor: 4.200

10.  Collaboration for rare disease drug discovery research.

Authors:  Nadia K Litterman; Michele Rhee; David C Swinney; Sean Ekins
Journal:  F1000Res       Date:  2014-10-31
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.